FIELD: crystal chemistry.
SUBSTANCE: invention relates to co-crystals containing N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), with Compound 1 being represented by the following structural formula:
and only one triglyceride, with the triglyceride being selected from glyceryltrioleate, glyceryltrioctanoate and glyceryltrilinoleate, as well as to the methods for their obtaining and methods for treating cystic fibrosis using them.
EFFECT: treatment of cystic fibrosis with their help.
11 cl, 37 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID FORMS OF N-(4-(7-AZABICYCLO[2,2,1]HEPTAN-7-YL)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | 2010 |
|
RU2568608C2 |
| METHOD FOR OBTAINING MODULATORS OF CYSTIC FIBROUSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2010 |
|
RU2553989C2 |
| COMPOUNDS SUITABLE FOR USE AS ATR KINASE INHIBITORS | 2014 |
|
RU2687276C2 |
| METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING CFTR MEDIATED DISEASES | 2014 |
|
RU2718044C2 |
| SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[d][1,3]DIOXOL-5-YL)-N-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANE CARBOXAMIDE | 2011 |
|
RU2573830C2 |
| SOLID FORMS OF (R)-1-(2, 2-DIFLUOROBENZO[D][1, 3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE | 2011 |
|
RU2711481C2 |
| NOVEL CRYSTALLINE FORMS OF DIPEPTIDYLPEPTIDASE-IV INHIBITORS | 2012 |
|
RU2598072C2 |
| METHOD OF PRODUCING ATR KINASE INHIBITORS (EMBODIMENTS) | 2014 |
|
RU2720408C2 |
| COMPOUNDS APPLICABLE AS ATR KINASE INHIBITORS | 2020 |
|
RU2750148C1 |
| SOLID FORMS OF N-(7-AZABICYCLO[2,2,1]HEPTAN-7-YL-)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUIINOLINE-3-CARBOXAMIDE | 2009 |
|
RU2518479C2 |
